These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 549299)

  • 1. [Parathormone, calcitonin, 25-hydroxycalciferol and bone histology in patients with chronic renal insufficiency].
    Kokot F; Kuska J; Sledziński Z; Białas B; Luciak M
    Z Gesamte Inn Med; 1979 Nov; 34(22):665-70. PubMed ID: 549299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G; Schaefer K; Schulz A; Delling G
    Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
    Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
    J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How important is phosphate in the pathogenesis of renal osteodystrophy?
    Slatopolsky E; Rutherford WE; Hruska K; Martin K; Klahr S
    Arch Intern Med; 1978 May; 138 Spec No():848-52. PubMed ID: 646572
    [No Abstract]   [Full Text] [Related]  

  • 6. [Vitamin D metabolism and chronic kidney disease].
    Honda H; Sanada D; Akizawa T
    Clin Calcium; 2006 Jul; 16(7):1143-46. PubMed ID: 16816474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function.
    Messa P; Mioni G; Turrin D; Guerra UP
    Nephrol Dial Transplant; 1995 Dec; 10(12):2259-65. PubMed ID: 8808222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N; Tsubakihara Y
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
    Rahamimov R; Silver J
    Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure.
    Malluche HH; Faugère MC; Ritz E; Caillens G; Wildberger D
    Miner Electrolyte Metab; 1986; 12(2):113-8. PubMed ID: 3960014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration.
    Takamoto S; Onishi T; Morimoto S; Imanaka S; Tsuchiya H; Seino Y; Yokokawa T; Iida N; Kumahara Y
    Nephron; 1985; 40(3):286-91. PubMed ID: 3839293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal osteodystrophy: role of vitamin D and parathyroid hormone].
    Drüeke T; Ulmann A
    Nouv Presse Med; 1979 May; 8(23):1901-3. PubMed ID: 223122
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 17. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
    Ishii H; Wada M; Furuya Y; Nagano N; Nemeth EF; Fox J
    Bone; 2000 Feb; 26(2):175-82. PubMed ID: 10678413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis].
    Yoshida K; Hirayama A; Tanaka N; Yasukawa M; Saka M; Kaneko Y; Maruyama Y; Motomiya Y; Ozono S; Hirao Y
    Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1117-23. PubMed ID: 2287104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic renal insufficiency and secondary hyperparathyroidism in rats. Biochemical and histological evaluation].
    Virgós MJ; Menéndez-Rodríguez P; Serrano M; González-Carcedo A; Braga S; Cannata JB
    Rev Esp Fisiol; 1993 Dec; 49(4):241-7. PubMed ID: 8209101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.